


VACCINE TRIALS UNDER PROCESS


Groundbreaking vaccine trials

Shaping the future of global healthcare

COMPREHENSIVE OVERVIEW OF DIVERSE VACCINE ENDEAVORS



VACCINE FRONTIER












Vaccine Trials Under Process

	I			
Molecule	Indication	Phase	No. of Sites	No. of Patients
Hepatitis A Vaccine	Hepatitis A	III	5	224
Hexavalent (DTwP-IPV-Hep B-Hib)	DTwP/IPV/HepB/ Hib	111	12	1064
Varicella Vaccine (2 Trials)	Chicken Pox	III	6	344/424
sIPV	Polio	III	8	670
Rotavirus Vaccine	Rotavirus Gastroenteritis	III	10	1170
Meningococcal Vaccine	Meningitis	III	8	748
Inactivated Polio Vaccine	Polio	III	5	420
Quadrivalent Influenza Vaccine	Influenza	III	15	2100
PPSV 23	Pneumococcal	III	12	1760
Herpes Zoster	Herpes	III	7	360
Pneumococcal 13 valent	Pneumonia	III	8	700
Tdap Vaccine	Tet./Deph./Pert.	III	7	534

Current Status of Ongoing Vaccine Trials

Vaccine Trials Under Process



Conclusion

The landscape of infectious disease prevention is rapidly evolving with ongoing Phase III vaccine trials across various indications. From Hepatitis A to influenza, these trials are essential steps in advancing global public health. The diverse range of vaccines under investigation signifies a concerted effort to combat infectious diseases that pose significant threats to communities worldwide. The outcomes of these trials will not only impact the individuals directly involved but also contribute to the broader mission of creating a healthier and more resilient global population.